Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. It also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California. Show more

Location: 10275 Science Center Dr., Suite 1710, San Diego, CA, 92121, United States | Website: https://zentalis.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

101.5M

52 Wk Range

$1.01 - $5.44

Previous Close

$1.41

Open

$1.42

Volume

598,499

Day Range

$1.38 - $1.48

Enterprise Value

-206.8M

Cash

332.5M

Avg Qtr Burn

-37.88M

Insider Ownership

13.58%

Institutional Own.

80.34%

Qtr Updated

03/31/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Azenosertib (ZN-c3) (oral inhibitor of WEE1) +/- niraparib Details Ovarian cancer, Cancer, PARPi Resistant Ovarian Cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Azenosertib (ZN-c3) (oral inhibitor of WEE1) mono Details Cyclin E1+ platinum-resistant ovarian cancer (PROC)	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Azenosertib (ZN-c3) (oral inhibitor of WEE1) Details Uterine disease, Cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Azenosertib (ZN-c3) (oral inhibitor of WEE1) Details Cancer, Solid tumor/s	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Azenosertib (ZN-c3) (oral inhibitor of WEE1) w/ multiple chemo Details Ovarian cancer, Cancer, Platinum-resistant ovarian cancer	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Azenosertib (ZN-c3) + gemcitabine Details Cancer, Osteosarcoma	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Azenosertib (ZN-c3) (oral inhibitor of WEE1) Details Ovarian cancer, Cancer, Platinum Sensitive Ovarian Cancer	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Azenosertib (ZN-c3) + encorafenib and cetuximab Details Cancer, Metastatic colorectal cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ZN-d5 (oral selective inhibitor of B-cell lymphoma 2 (BCL-2)) + azenosertib Details Acute myeloid leukemia, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ZN-d5 (oral selective inhibitor of B-cell lymphoma 2 (BCL-2)) Details Cancer, relapsed or refractory light chain amyloidosis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ZN-c5: Oral SERD (Monotherapy) Details Breast cancer, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ZN-c5 (Oral SERD) +Verzenio® (abemaciclib) Details Breast cancer, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.